Continuous Flow Lorazepam Synthesis for Safer Scale-Up

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing synthesis methods for Lorazepam face challenges such as process irreproducibility, difficulty in scaling, use of harsh oxidizing agents, and safety concerns, leading to manufacturing delays and shortages.

Innovation Solution

A continuous flow reactor system is employed for Lorazepam synthesis, utilizing a series of steps including acylation, cyclization, oxidation, Polonovski-type rearrangement, and hydrolysis, using greener reagents and solvents to achieve high yield and purity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If batch production method is used for Lorazepam synthesis, then the process is simpler to operate, but the production time is long and scaling is difficult

Engineering Contradiction:
Improveease of operationVSAvoidproduction time
Core Design Contradiction:
Ease of operationVSProductivity

Solution Approach 1:

The patent transitions from batch production to continuous flow production, where reactants continuously flow through the reactor system enabling uninterrupted synthesis. This eliminates idle times between batches and allows sustained production, directly addressing the long production time issue while maintaining operational simplicity through automated flow control

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

The synthesis process is divided into discrete modular steps (acylation, cyclization, oxidation, rearrangement, hydrolysis) that can be performed in sequence or parallel. This segmentation enables independent optimization of each step and facilitates easier scaling by adding or removing modules without redesigning the entire process

Inventive Principle:
Principle #1Segmentation

2Device complexity

If batch production is used, then equipment requirements are simpler, but the footprint is large and scheduling is complex

Engineering Contradiction:
Improveequipment complexityVSAvoidfootprint
Core Design Contradiction:
Device complexityVSArea of stationary object

Solution Approach 1:

The patent employs fluid flow systems to transport reactants and products through the synthesis process, replacing mechanical batch processing equipment. This hydraulic approach enables compact reactor design where reactions occur in continuous flow through small-diameter tubing and chambers, dramatically reducing the physical footprint while simplifying equipment requirements through standardized flow components

Inventive Principle:
Principle #29Pneumatics and hydraulics

3Productivity

If harsh oxidizing agents like persulfate are used, then the oxidation step is more effective, but safety risks increase and environmental impact worsens

Engineering Contradiction:
Improveoxidation efficiencyVSAvoidsafety risks
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the oxidation step by replacing harsh oxidizing agents (persulfate) with milder alternatives that achieve comparable or superior oxidation efficiency. This parameter change reduces safety risks and environmental impact while maintaining productivity, demonstrating that effective synthesis does not require hazardous reagents

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent converts the potential harm of oxidation reactions by using controlled, selective oxidizing conditions that minimize side reactions and byproduct formation. The oxidation step is designed to be highly selective for the desired transformation, turning a potentially hazardous process into a clean, efficient step that improves overall process safety and sustainability

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

4Manufacturing precision

If additional synthesis steps are added to improve yield, then the purity increases, but the production time increases

Engineering Contradiction:
ImprovepurityVSAvoidproduction time
Core Design Contradiction:
Manufacturing precisionVSLoss of time

Solution Approach 1:

The patent merges multiple synthesis operations into integrated continuous flow steps where reactions occur in sequence without intermediate isolation. This merging maintains high purity through controlled reaction conditions while eliminating the time losses associated with batch processing, filtration, and transfer operations between steps

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent performs preliminary optimization of reaction conditions, stoichiometry, and flow rates during the process design phase. This preliminary action ensures that each synthesis step proceeds with high selectivity and efficiency, achieving the desired purity in fewer steps and reducing overall production time by preventing the need for additional purification steps

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method provides a robust and efficient process for Lorazepam synthesis, enabling accelerated scale-up to large-scale manufacturing with higher yield, purity, and safety, reducing overall time from days to minutes.

Implementation Method 1

oxidizing delorazepam (4) by mixing a solution comprising delorazepam (4) with a solution comprising a peroxide reagent and a solution comprising a rhenium oxide catalyst to yield 7-chloro-5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepine 4-oxide (delorazepam N-oxide, (5))

Methodology Applied
Scientific EffectCatalysis: Catalysis

Implementation Method 2

hydrolyzing lorazepam acetate (6) by mixing a solution comprising lorazepam acetate (6) and a solution comprising a base and an additive to yield lorazepam (1)

Methodology Applied
Scientific EffectHydrolysis: Hydrolysis

Data Source

PatentUS20260062390A1Continuous flow synthesis of lorazepam
Publication Date: 2026.03.05 CONTINUITY PHARMA LLC
  • US20260062390A1 patent drawing
  • US20260062390A1 patent drawing
  • US20260062390A1 patent drawing

AI summary

A method for synthesis of Lorazepam in a continuous flow using continuous flow reactor, in which method comprises five steps including N-acylation, diazepine ring closure, imine N-oxidation, Polonovski-type rearrangement, and ester hydrolysis; a green reagent comprising a peroxide reagent and rhenium oxide catalyst for N-oxidation of delorazepam; and an ammonium source combination for the synthesis of delorazepam.